Life Science Investing OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
Placement to Institutional and Sophisticated Investors, Appointment of Joint Broker,Issue of Equity & TVR
